Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 3851
An employee of the Licensor, is the inventor who has submitted the following disclosures, a portion of which constitute the Invention (i) UA1524, Therapeutic Monoclonal IgA Antibodies to Cryptosporidium Antigens of 500KDa and Less Than 1,000KDa; (ii) UA1525, Anti-GP23 Antigen Monoclonal IgA Antibodies for Treatment of Cryptosporidiosis, G9H4 and H8H2 and (iii) UA1526, Monoclonal IgA Antibody 1B8 Directed to Cryptosporidium 200KDa Antigen.
IPSCIO Record ID: 29179
An employee of the Licensor is the Inventor who has submitted a disclosure Monoclonal Antibodies Reactive with Multiple Neutralization-Sensitive Surface Epitopes as a Source of Treatment of Enteric Cryptosporidiosis.
IPSCIO Record ID: 29180
Employees of the Licensor are the inventors of Anti-Cryptosporidium parvum Sporozoite IgA Monoclonal Antibody.
IPSCIO Record ID: 29178
Licensed Products shall mean hyperimmune hen egg yolks containing Anti-Cryptosporidium antibodies derived from the Invention. The employees of the Licensee, are The Inventors who have disclosed an invention, Hyperimmune Egg Yolks as a Source of Anti-Cryptosporidium Neutralizing Antibodies Suitable for Passive Immune.
IPSCIO Record ID: 29176
IPSCIO Record ID: 29177
IPSCIO Record ID: 6244
Licensor wishes to provide Licensee, with the technology and all other information and know how related to the treatment of Cryptosporidium parvum and Clostridium difficile infections in order to enable Licensee to manufacture finished pharmaceutical products with said indications.
IPSCIO Record ID: 1395
(a) an exclusive, worldwide license, including the right to grant sublicenses, to develop, make, have made, import, use, sell, offer to sell or have sold Licensed Products and related cell lines, including the Sp2/0 Cell Line.
â€œHumanized Antibody(ies)â€ means the humanized form of the Murine Antibody.
â€œLicensed Product(s)â€ means products, for any use, incorporating substantially all of the Humanized Antibody or any modification, variant or fragment of the Humanized Antibody containing at least one variable region of the Humanized Antibody.
â€œMurine Antibody(ies)â€ means, subject to Section 2.01(b), the murine monoclonal antibody designated as â€œPRO 140â€ directed against the Target Antigen.
IPSCIO Record ID: 28073
Type I Technology shall mean the recombinant viral antigens and murine antibody clones and Type II Technology shall mean the animal model.
1. Antigens cloned, expressed and purified in the Tyrrell University laboratory as follows
Human Hepatitis B(HBV) Core Antigen (short)
Duck Hepatitis B(DHBV) Surface Antigen
Duck Hepatitis B(DHBV) Polymerase Protein
Duck Hepatitis B(DHBV) Core Protein
2. Murine antibody clones developed in the Tyrrell University laboratory as follows
Monoclonal Antibody 1D12 to HBV core antigen
Monoclonal antibodies 2C12, 2D12, 2C11, 2A12, 4A10, 1F9, 2G11 to HBV surface antigen
Monoclonal Antibody 3A8, 2C4 to HBV Polymerase
Monoclonal Antibody 1F4 to DHBV Surface Antigen
Monoclonal Antibodies 9A8, 8D6, 7G4, 7G5, 7G10, 9F2, 9G8, 1A9, 4A9, 1H5 to DHBV Core Antigen.
3. Animal model as follows
Hepatitis B Duck Model
Including any replications of progeny of the above made by the Licensee and, if that which is made by the Licensee, constitutes cells or DNA molecules. Type II Technology includes all modifications, improvements and variants thereof and any data or information in relating thereto including sequence information.